Recombinant MERS-CoV Spike RBD His-tag Protein, CF

Recombinant MERS-CoV Spike RBD His-tag (Catalog # 10621-CV) binds Recombinant Human DPPIV/CD26 (High Purity Dimer) Protein (9168-SE) in a functional ELISA.

2 μg/lane of Recombinant MERS-CoV Spike RBD His-tag Protein (Catalog # 10621-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 35-45 kDa.

In a functional flow cytometry test, (A) Recombinant MERS-CoV Spike RBD His-tag Protein (Catalog # 10621-CV) binds to HEK293 human embryonic kidney cell line transfected with recombinant human CD26/DPPIV and EGFP. Ligand binding was detected by staining cells with APC-conjugated anti-His Monoclonal Antibody (IC050A), which does not stain the cells in the absence of recombinant protein (B).

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant MERS-CoV Spike RBD His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA with Recombinant Human DPPIV/CD26 (High Purity Dimer) (Catalog # 9168-SE).
• Source: Chinese Hamster Ovary cell line, CHO-derived mers-cov Spike RBD protein
  

  MERS-CoV Spike RBD (Glu367-Tyr606) Accession # YP_007188579.1	HP	GGGSGGGSGGGS	HHHHHH
  N-terminus			C-terminus

• Accession #: YP_007188579.1
• N-terminal Sequence: Glu367 & Lys369
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 28 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 35-45 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant MERS-CoV Spike RBD His-tag Protein, CF

• Spike RBD

Background

MERS-CoV (also known as HCoV-EMC), which causes the Middle East Respiratory Syndrome (MERS), was first reported in Saudi Arabia in 2012 as a novel coronavirus (1). Coronaviruses are a family of viruses that are commonly comprised of a large plus-strand RNA genome and four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N). There are two well-known human coronavirus families that infect humans: Alpha coronaviruses which includes HCoV-229E and HCoV-NL63; beta coronaviruses that includes MERS-CoV, HCov-OC43, Severe Acute Respiratory Syndrome (SARS-CoV), and global pandemic Covid-19 (SARS-CoV2) (2). The MERS-CoV Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry, and it consists of two subunits, S1 and S2. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3). Located within the S1 subunit is the receptor binding domain (RBD). The RBD is responsible for the binding of MERS-CoV to dipeptidyl peptidase IV (DPP4, also known as human CD26) (4). The RBD of MERS-CoV shares 24% and 21% amino acid sequence (aa) identity with SARS-CoV RBD and SARS-Cov2 RBD, respectively. The low aa sequence identity is consistent with the finding that MERS-CoV and SARS-CoV bind different cellular receptors (4). The S1 subunit, especially the RBD region, of MERS-CoV was commonly targeted for vaccinations or antiviral therapies (5-7).

1. Zaki, A.M. et al. (2012) N. Engl. J. Med. 367:1814.
2. Ogimi, C. et al. (2020) J Pediatric Infect Dis Soc doi: 10.1093/jpids/piaa037.
3. Li, Y. et al. (2019) Engineering. 5:940.
4. Raj, V.S. et al. (2013) Nature 495:251.
5. Corti, D. et al. (2016) J. Infect. Public Health 9:231.
6. Tang, X.C. et al. (2014) Proc. Natl. Acad. Sci. USA 111:E2018.
7. Jiang, L. et al. (2014) Sci. Transl. Med. 6:234ra59.

Bioinformatics

• Uniprot:
  • YP_007188579.1()